JP Gilbert
Senior Director Xenon Pharmaceuticals
Seminars
Wednesday 23rd September 2026
Selective Potentiation of Nav1.1 Corrects Network Function and Disease Phenotypes in a Dravet Syndrome Model
2:30 pm
- Demonstrating how targeted ion channel modulation can treat clinically relevant phenotypes through integrated electrophysiology, behavioral and bioinformatics approaches
- Focusing on translational measures to evaluate the potential for disease modification with Nav1.1 modulation
- Highlighting a multi-layered preclinical strategy to evaluate target biology and therapeutic potential prior to clinical development
